YieldMax TSLA Option Income Strategy ETF vs State Street SPDR S&P Biotech ETF — how do they compare? YieldMax TSLA Option Income Strategy ETF trades at $21.67, while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| TSLY | XBI | |
|---|---|---|
Sector | Income / Options Overlay | Broad Market / Factor |
52-Week High | $48.25 | $164.28 |
52-Week Low | $20.49 | $86.92 |
Signals from Pluang's Aura AI — not financial advice
TSLY trades at $21.62, down 0.51% today, with a bearish technical outlook per moving averages and mixed oscillators. The ETF maintains high dividend distributions, with recent payouts ranging from $0.21 to $0.52 weekly, but faces capped upside risk due to its option income strategy structure. Recent news highlights concerns over missed Tesla rallies and volatility shifts, impacting sentiment.
Outlook is cautious due to structural limitations in capturing Tesla's gains, with risks including volatility dependency and competitive ETF strategies. The high yield attracts income seekers, but total return potential may be constrained if Tesla appreciates significantly, warranting careful risk assessment for equity-focused investors.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Trailing returns across standard periods
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →